An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 230 participants.
Also called NCT01638507
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 230 participants
- Sponsor
- Registry
-
NCT01638507
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01638507. Allocation not applicable; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2015-11-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
- Acronym
- RI-US
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Resolute Integrity Stent
- Lead sponsor
- Medtronic Vascular
Record details
- Record id
cardio:ct-nct01638507- Content hash
fe3a84ed3ab086a042bbab924fc6056fd351a3ae5a53c7a318cb166ee78c4a00